Entrepreneurs In Residence

Entrepreneurs in Residence are industry experts who provide guidance to Yale researchers as part of the application process, meeting one-on-one with them to discuss strategy and best practices.

Entrepreneurs in Residence

Susan Froshauer, Ph.D.
President and CEO of CURE & CURE Innovations

Dr. Froshauer is President and CEO of CURE and President of CURE Innovations, LLC. She is an experienced scientist, mentor, entrpereneur and angel investor with skill at connecting academice expertise and technology with the commercial sector. In addition to the Yale Entrepreneurial Institute, Susan is involved with the CTNEXT funded group, SECT Tech, the Creative Arts Workshop and the Angel Investor Forum. Prior to joining CURE, Dr. Froshauer was Director of the Technology Exchange Portal at the University of Connecticut’s Office of Economic Development. In this role, Susan assisted Connecticut-based entrepreneurs and organizations with initiatives that train students, create jobs and contribute to economic development. She connected ideas with business expertise, business plans with investors and industry with scholars. Until 2010, Susan served as President and CEO of Rib-X Pharmaceuticals which she cofounded in New Haven in 2000. Under her leadership, Rib-X raised more than $160 million in private equity, bridge financing and government grants and built an emerging pipeline of antibiotics to treat serious hospital infections. Prior to Rib-X, Susan served as a member of Pfizer’s Strategic Alliance Groups where she was part of a team involved in the creation of a $200 million investment portfolio that transformed the Pfizer global research and development strategy. She received a Ph.D. in Microbiology and Molecular Genetics from Harvard University and a B.A. from Conecticut College. She performed post-doctoral research at Yale Medical School in the Department of Cell Biology as a Jane Coffin Child’s Fellow.

Ron Lennox, D.Phil.
Partner, Alia Ventures

Ron invests in the biotechnology and molecular diagnostic sectors. He has served on the boards of eighteen companies including General Surgical Innovations, Inc. (acquired by Tyco International Corp.), GeneOhm Sciences, Inc. (acquired by Becton Dickinson), Protometrix, Inc. (acquired by Invitrogen Corp.), and Applied Molecular Evolution Inc. (acquired by Eli Lilly). He was founding Chairman of Amicus Therapeutics (NASDAQ: FOLD) and Chairman of Bikam Therapeutics (responsible for sale to Shire in 2014). He also was CEO of Protometrix, Inc. as well as of CGI Pharmaceuticals, Inc. Prior to the founding of CHL Medical Partners, Ron was a general partner at Hancock Venture Partners (now HarbourVest Partners) where he invested in sixteen healthcare companies, ten of which had successful IPOs. Ron graduated from the University of Glasgow with a B.Sc. in Molecular Biology, Oxford University where he received a D.Phil. in Cell Biology and the Wharton School of the University of Pennsylvania.